TY - JOUR
T1 - Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori Eradication in patients with nonulcer dyspepsia
AU - Sheu, Bor Shyang
AU - Yang, Hsiao Bai
AU - Wang, Yen Lin
AU - Chuang, Chiao Hsiung
AU - Huang, Ay Huey
AU - Wu, Jiunn Jong
N1 - Funding Information:
The authors appreciate the support from Taiwan Astrazeneca Comp.
Funding Information:
Manuscript received January 3, 2001; accepted June 15, 2001. From the Departments of *Internal Medicine, †Pathology, and §Medical Technology, National Cheng Kung University, Tainan; and ‡Chung Hwa College of Medical Technology, Tainan, Taiwan. This study was supported by research grants from the National Health Research Institute (NHRI-GT-EX89S941C) of Taiwan.
PY - 2001
Y1 - 2001
N2 - This study aimed to test whether pretreatment gastric pathology in H. pylori-infected nonulcer dyspepsia (HpNUD) patients is relevant to and predictive of the symptomatic response after H. pylori eradication. Anti-H. pylori triple therapy was administered to 250 HpNUD patients, enrolled as the therapy group. In addition, 60 patients were enrolled as the control group, in which omeprazole was an alternatives to the triple therapy. Pretreatment gastric histology was evaluated thoroughly by the updated Sydney system. A [13C] urea breath test was also performed to evaluate the H. pylori eradication two months and 12 months later. For each patient, the baseline, month 2, and month 12 symptom scores were assessed for the month 2 or month 12 residual symptom ratio (RSR-2m or RSR-12m), calculated from: 100% × month 2 or month 12 score/baseline score. Based on either RSR-2m or RSR-12m, patients were categorized as good response (RSR < 50%), moderate response (50-70%), and poor response (>70%) subgroups in both therapy and control groups to define the short-term and long-term symptomatic responses. Patients with successful H. pylori eradication in the therapy group showed a higher incidence of good symptomatic response (RSR < 50%) than those from the control group (month 2:30.3 vs 12%, P < 0.05; month 12:34.7 vs 17.1%, P < 0.05). Univariate and multivariate analysis disclosed that patients with a higher acute inflammation score (AIS) and the lowest incidence of lymphoid follicles (LF) at pretreatment gastric histology are predisposed to having a good symptom response after H. pylori eradication (P < 0.05). For HpNUD patients who have an AIS of more than three and an absence of LF at gastric histology, more than 85% had good short-term (month 2) and long-term (month 12) symptomatic relief after H. pylori eradication. In conclusion, nearly 30% of HpNUD patients can obtain symptomatic relief following H. pylori eradication. The pretreatment gastric histology of HpNUD can be helpful to monitor the symptomatic response after H. pylori eradication.
AB - This study aimed to test whether pretreatment gastric pathology in H. pylori-infected nonulcer dyspepsia (HpNUD) patients is relevant to and predictive of the symptomatic response after H. pylori eradication. Anti-H. pylori triple therapy was administered to 250 HpNUD patients, enrolled as the therapy group. In addition, 60 patients were enrolled as the control group, in which omeprazole was an alternatives to the triple therapy. Pretreatment gastric histology was evaluated thoroughly by the updated Sydney system. A [13C] urea breath test was also performed to evaluate the H. pylori eradication two months and 12 months later. For each patient, the baseline, month 2, and month 12 symptom scores were assessed for the month 2 or month 12 residual symptom ratio (RSR-2m or RSR-12m), calculated from: 100% × month 2 or month 12 score/baseline score. Based on either RSR-2m or RSR-12m, patients were categorized as good response (RSR < 50%), moderate response (50-70%), and poor response (>70%) subgroups in both therapy and control groups to define the short-term and long-term symptomatic responses. Patients with successful H. pylori eradication in the therapy group showed a higher incidence of good symptomatic response (RSR < 50%) than those from the control group (month 2:30.3 vs 12%, P < 0.05; month 12:34.7 vs 17.1%, P < 0.05). Univariate and multivariate analysis disclosed that patients with a higher acute inflammation score (AIS) and the lowest incidence of lymphoid follicles (LF) at pretreatment gastric histology are predisposed to having a good symptom response after H. pylori eradication (P < 0.05). For HpNUD patients who have an AIS of more than three and an absence of LF at gastric histology, more than 85% had good short-term (month 2) and long-term (month 12) symptomatic relief after H. pylori eradication. In conclusion, nearly 30% of HpNUD patients can obtain symptomatic relief following H. pylori eradication. The pretreatment gastric histology of HpNUD can be helpful to monitor the symptomatic response after H. pylori eradication.
UR - http://www.scopus.com/inward/record.url?scp=0035215285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035215285&partnerID=8YFLogxK
U2 - 10.1023/A:1012727513166
DO - 10.1023/A:1012727513166
M3 - Article
C2 - 11768263
AN - SCOPUS:0035215285
SN - 0163-2116
VL - 46
SP - 2700
EP - 2707
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 12
ER -